Technical Data
T9160-41
Tumor Necrosis Factor beta, Recombinant, Human (TNFb)
5ug
20ug
Growth Factors, Cytokines Storage: -20CShipping: RT
Recombinant Human TNF-beta (Lymphotoxin) is a single, non-glycosylated, polypeptide chain containing 171 amino acids and having a molecular mass of 18645 Dalton. Recombinant Human Tumor Necrosis Factor-beta is purified by standard chromatographic techniques.

Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Met-Val-Arg-Ser-Ser.

Dimers and Aggregates:
1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:
TNF-beta is fully biologically active when compared to standard. The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is less then 0.05ng/ml, corresponding to a Specific Activity of 2 x10e6 IU/mg.

Endotoxin:
0.1ng/ug (IEU/ug) of TNF-beta.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm using the absorbency value of 1.082 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a calibrated solution of TNF-beta as a Reference Standard.

Reconstitution:
Reconstitute the lyophilized TNF-beta in sterile 18M-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
Source: E. coli
Purity: 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.
Concentration: ~0.1mg/ml
Form: Supplied as a lyophilized powder. No additives.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Polymorphisms within the genes encoding TNF-alpha and TNF-beta associate with the incidence of post-transplant complications in recipients of allogeneic hematopoietic stem cell transplants. Bogunia-Kubik K, Arch Immunol Ther Exp (Warsz) 2004 Jul-Aug;52(4):240-9 2. Are postoperative complications genetically determined by TNF-beta NcoI gene polymorphism? Kahlke V, Schafmayer C, Seegert D, Surgery 2004 Apr;135(4):365-73; discussion 374-5 3. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. Goyal A, Kazim SN, Malhotra V, J Med Virol 2004 Jan;72(1):60-5 4. TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction. Um JY, An NH, J Mol Neurosci 2003;21(2):167-71 5. Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumours. Holzer G, Pfandlsteiner T, Trieb K, Anticancer Res 2003 May-Jun;23(3C):3057-9 6. Influence of the TNF-alpha and TNF-beta polymorphisms upon infectious risk and outcome in surgical intensive care patients. Calvano JE, Um JY, Hahm SJ, Lowry SF, Surg Infect (Larchmt) 2003 Summer;4(2):163-9.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.